Novabiotics - a leading clinical-stage biotechnology company
Novabiotics about us Novabiotics clinical studies Novabiotics pipeline Novabiotics our news Novabiotics contact

NovaBiotics are delighted to announce that our CARE CF 1 phase 2b clinical trial data for oral Lynovex in infectious pulmonary exacerbations of cystic fibrosis is published today in PLOS ONE. Our findings further support the potential of Lynovex® as game-changer in CF therapy.

Our Lynovex Infographic explains more and you can access the newly published research article here PLOS ONE CARE CF 1